These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 1342043)

  • 21. The first Japanese pediatric case of obsessive-compulsive disorder who responded to a selective serotonin re-uptake inhibitor.
    Furusho J; Kubagawa T; Saitoh N; Matsuzaki K; Yamakawa H; Iikura Y
    Pediatr Int; 2000 Aug; 42(4):451-2. PubMed ID: 10986886
    [No Abstract]   [Full Text] [Related]  

  • 22. Sertraline and mental retardation with obsessive-compulsive disorder.
    Wiener K; Lamberti JS
    Am J Psychiatry; 1993 Aug; 150(8):1270. PubMed ID: 8328577
    [No Abstract]   [Full Text] [Related]  

  • 23. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder.
    Barr LC; Goodman WK; Anand A; McDougle CJ; Price LH
    Am J Psychiatry; 1997 Sep; 154(9):1293-5. PubMed ID: 9286191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Experimental therapeutics for refractory obsessive-compulsive disorder: translational approaches and new somatic developments.
    Berlin HA; Hamilton H; Hollander E
    Mt Sinai J Med; 2008; 75(3):174-203. PubMed ID: 18704978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impaired set-shifting ability and therapeutic response in obsessive-compulsive disorder.
    Fontenelle L; Marques C; Engelhardt E; Versiani M
    J Neuropsychiatry Clin Neurosci; 2001; 13(4):508-10. PubMed ID: 11748320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Obsessive-compulsive disorder.
    Veale D; Roberts A
    BMJ; 2014 Apr; 348():g2183. PubMed ID: 24709802
    [No Abstract]   [Full Text] [Related]  

  • 27. Obsessive-compulsive spectrum disorders: effective treatment with paroxetine.
    Ravindran AV; Lapierre YD; Anisman H
    Can J Psychiatry; 1999 Oct; 44(8):805-7. PubMed ID: 10566112
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacotherapy of obsessive-compulsive disorder: experience with the selective serotonin reuptake inhibitors.
    Vythilingum B; Cartwright C; Hollander E
    Int Clin Psychopharmacol; 2000 Aug; 15 Suppl 2():S7-13. PubMed ID: 11110014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of selective serotonin reuptake inhibitors on thought-action fusion, metacognitions, and thought suppression in obsessive-compulsive disorder.
    Besiroglu L; Çetinkaya N; Selvi Y; Atli A
    Compr Psychiatry; 2011; 52(5):556-61. PubMed ID: 21109243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiobsessional effect of risperidone add-on treatment in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder may be dose-dependent.
    Ramasubbu R
    Arch Gen Psychiatry; 2002 May; 59(5):472; author reply 472-3. PubMed ID: 11982460
    [No Abstract]   [Full Text] [Related]  

  • 31. Patients with obsessive-compulsive disorder (OCD) displayed cognitive deficits consistent with a dysfunction of the dorsolateral-striatal circuit.
    Fontenelle LF; Mendlowicz MV; Versiani M
    Psychol Med; 2004 Oct; 34(7):1367-8; author reply 1368-9. PubMed ID: 15697063
    [No Abstract]   [Full Text] [Related]  

  • 32. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
    Weiss EL; Potenza MN; McDougle CJ; Epperson CN
    J Clin Psychiatry; 1999 Aug; 60(8):524-7. PubMed ID: 10485634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A review of antipsychotics in the treatment of obsessive compulsive disorder.
    Fineberg NA; Gale TM; Sivakumaran T
    J Psychopharmacol; 2006 Jan; 20(1):97-103. PubMed ID: 16204331
    [No Abstract]   [Full Text] [Related]  

  • 34. Why have early investigational therapies of obsessive-compulsive disorder failed to materialise?
    Marazziti D; Dell'Osso L
    Expert Opin Investig Drugs; 2015 Apr; 24(4):455-8. PubMed ID: 25599971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comorbid obsessive compulsive and major depressive disorder.
    Ninan PT
    Psychopharmacol Bull; 2001; 35(1):77-83. PubMed ID: 12397872
    [No Abstract]   [Full Text] [Related]  

  • 36. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Obsessive-compulsive disorder: evaluation of clinical and biological circadian parameters during fluoxetine treatment.
    Millet B; Touitou Y; Poirier MF; Bourdel MC; Amado I; Hantouche EG; Bogdan A; Olié JP
    Psychopharmacology (Berl); 1999 Oct; 146(3):268-74. PubMed ID: 10541726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fluoxetine versus phenelzine in obsessive-compulsive disorder.
    Golwyn DH; Sevlie CP
    Am J Psychiatry; 1999 Jan; 156(1):159-60. PubMed ID: 9892321
    [No Abstract]   [Full Text] [Related]  

  • 39. Early-onset obsessive-compulsive disorder.
    Bhattacharyya S; Girishchandra BG; Khanna S
    Can J Psychiatry; 2003 Jun; 48(5):352-3. PubMed ID: 12866350
    [No Abstract]   [Full Text] [Related]  

  • 40. Non-selective effects of selective serotonin reuptake inhibitors.
    Zurowski B; Kordon A; Wahl K; Hohagen F
    Biol Psychiatry; 2008 Jan; 63(1):e5; author reply e7. PubMed ID: 17693390
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.